dr. bardia on sacituzumab govitecan in triple-negative breast cancer
Published 6 years ago • 2.7K plays • Length 2:40Download video MP4
Download video MP3
Similar videos
-
1:47
dr. bardia on sacituzumab govitecan in tnbc
-
2:23
dr aditya bardia discusses the advantages of sacituzumab govitecan for triple-negative breast cancer
-
3:31
the ascent of sacituzumab govitecan in metastatic tnbc | aditya bardia
-
0:59
dr. bardia on the results of the ascent trial in previously treated metastatic tnbc
-
5:16
study of sacituzumab govitecan for triple-negative breast cancer
-
1:26
antibody drug conjugate sacituzumab govitecan shows efficacy in tnbc
-
0:57
dr. bardia on the role of the microenvironment in tnbc
-
6:44
antibody-drug conjugates in treating tnbc
-
1:36
real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer
-
2:10
dr aditya bardia on how combining sacituzumab govitecan, talazoparib amplifies treatment response
-
1:29
aditya bardia, md, mph, discusses the design of newly approved sacituzumab govitecan
-
1:15
dr. bardia on the need to develop additional therapies in metastatic tnbc
-
6:17
antibody-drug conjugates in tnbc: sacituzumab govitecan
-
3:10
ascent trial: sacituzumab govitecan for tnbc
-
1:08
ascent-05: sacituzumab govitecan and pembrolizumab in tnbc
-
0:58
dr. isaacs discusses sacituzumab govitecan in tnbc
-
0:49
dr. graff on the fda approval of sacituzumab govitecan in tnbc
-
2:44
dr aditya bardia forecasts what’s to come for the ascent trial in triple-negative breast cancer
-
1:58
ascent-04: sacituzumab govitecan and pembrolizumab in pd-l1-positive tnbc